Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Stereotactic Body Radiation Therapy Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic Hepatocellular Carcinoma

NCT05917431 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT05917431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05917431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Stereotactic Body Radiation Therapy Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic Hepatocellular Carcinoma
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 2
Overall status
Recruiting
Start date
June 30, 2023
Completion date
December 30, 2026
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic disease, unresectable hepatocellular carcinoma